Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel sağkalım özellikleri
Küçük Resim Yok
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Ege Üniversitesi (EÜ) Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan prostat kanseri (PK) tanılı 4792 hastanın epidemiyolojik özellikleri, tedavi modaliteleri ve sağkalım özelliklerinin tanımlanması amaçlanmıştır. Gereç ve Yöntem: EÜ Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan PK verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ (Dünya Sağlık Örgütü) ve SEER (Surveillance, Epidemiolgy, and End Results) sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistiksel analizlerde Kikare, General Linear Model, Kaplan Meier sağkalım analizleri uygulanmıştır. Kaplan-Meier Sağkalım analizinde Log Rank(Mantel-Cox), Breslow(Generalized Wilcoxon) ve TaroneWare istatistikleri kullanılmıştır. İstatistiksel analizlerde p<0,05 değeri anlamlı kabul edilmiştir. Bulgular: PK tanılı 4792 hasta verisi analiz edilmiştir. Olgularımızda PK’ne en çok 60-69 yaş grubunda rastlanmaktadır. Histopatolojik olarak en sık “asiner adenokarsinom” görülmektedir. Evrelendirme çalışması yapılabilen PK’lerinde lokalize dönemin %61,2 oran ile en fazla olduğu saptanmıştır. PK’lerinin görülüşünde yıllara göre doğrusal bir artış dikkat çekmektedir. Mortalitede ise 2008’e kadar doğrusal artış daha sonra azalış vardır. PK olgularımızda ortanca genel sağkalım(GSK) 120 aydır, tüm olgular için 5 ve 10 yıllık GSK’lar %74,2 ve %55,2 bulunmuştur.5 yıllık GSK oranları lokalize, lokal ileri ve metastatik evrelerde sırasıyla %86,3, %78,1 ve %21,7 saptanırken 10 yıllık GSK için sırasıyla %70, %62,7 ve %14’dür. Lokal ve lokal ileri evrelerde tedavi alanlarda sağkalımlarda anlamlı bir fark elde edilirken metastatik evrede anlamlı sonuç kaybolmaktadır. Sonuç: EÜ Hastanesi Kanser veri tabanında bulunan 4792 PK’li bu seri tek merkez olarak Türkiye’deki en geniş PK serisidir. PK olgularımızda 5 ve 10 yıllık GSK oranları sırasıyla %74,2 ve %55,2 bulunmuştur. Evrelere göre tedavilerin GSK’lar üzerine katkıları lokal ve lokal ileri evrede anlamlı bulunurken metastatik evrede bu anlamlılık kalmamaktadır.
Aim: The aim of this study is to evaluate the epidemiological, treatment modality and survival characteristics of 4792 patients with Prostate Cancer(PC) who were treated at Ege University Hospital (EUH). Materials and Methods: The data were recorded using the CANREG programme. WHO (World Health Organization) and SEER (Surveillance, Epidemiolgy, and End Results) system were considered for classification and survival analysis. Chi-square test, General Linear Model and KaplanMeier survival analysis were done. Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and Tarone-Ware models were used for Kaplan-Meier survival analyses. p value <0.05 was considered significant. Results: Data of 4792 PC patients were analysed. PC was mostly seen in the age group of 60-69 years. Most common histological type was “acinary adenocarcinoma”. Localized disease was most common (61,2%) among patients who could be staged. There is a linear increase in prostate cancer according to years. There is a linear increase in mortality until 2008, then decrease afterwards. Median survival was 120 months. Five and 10-year overall survival (OS) rates were 74.2% and 55.2% respectively. Five-year OS rates for localized, locally advanced and metastatic disease were 86.3%, 78.1% and 21.7% respectively whereas 10-year OS rates were 70%, 62.7% and 14% respectively. Survival rates differ significantly in patients who were treated for localized and locally advanced disease while the difference disappeared for metastatic disease. Conclusions: This is the largest prostate cancer data of a single center in Turkey with 4792 cases registered at EUH Cancer Database. Five and 10 year-OS rates were 74.2% and 55.2% respectively. Survival rates differ significantly in patients who were treated for localized and locally advanced disease while the difference disappeared for metastatic disease.
Aim: The aim of this study is to evaluate the epidemiological, treatment modality and survival characteristics of 4792 patients with Prostate Cancer(PC) who were treated at Ege University Hospital (EUH). Materials and Methods: The data were recorded using the CANREG programme. WHO (World Health Organization) and SEER (Surveillance, Epidemiolgy, and End Results) system were considered for classification and survival analysis. Chi-square test, General Linear Model and KaplanMeier survival analysis were done. Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and Tarone-Ware models were used for Kaplan-Meier survival analyses. p value <0.05 was considered significant. Results: Data of 4792 PC patients were analysed. PC was mostly seen in the age group of 60-69 years. Most common histological type was “acinary adenocarcinoma”. Localized disease was most common (61,2%) among patients who could be staged. There is a linear increase in prostate cancer according to years. There is a linear increase in mortality until 2008, then decrease afterwards. Median survival was 120 months. Five and 10-year overall survival (OS) rates were 74.2% and 55.2% respectively. Five-year OS rates for localized, locally advanced and metastatic disease were 86.3%, 78.1% and 21.7% respectively whereas 10-year OS rates were 70%, 62.7% and 14% respectively. Survival rates differ significantly in patients who were treated for localized and locally advanced disease while the difference disappeared for metastatic disease. Conclusions: This is the largest prostate cancer data of a single center in Turkey with 4792 cases registered at EUH Cancer Database. Five and 10 year-OS rates were 74.2% and 55.2% respectively. Survival rates differ significantly in patients who were treated for localized and locally advanced disease while the difference disappeared for metastatic disease.
Açıklama
Anahtar Kelimeler
[No Keywords]
Kaynak
Ege Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
59
Sayı
supplement
